Patents by Inventor John Minna

John Minna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11865157
    Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).
    Type: Grant
    Filed: January 20, 2023
    Date of Patent: January 9, 2024
    Assignees: University of Houston System, The Board of Regents of the University of Texas System
    Inventors: Damith Gomika Udugamasooriya, Aaron Raymond, John Minna
  • Publication number: 20230218708
    Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).
    Type: Application
    Filed: January 20, 2023
    Publication date: July 13, 2023
    Applicants: University of Houston System, The Board of Regents of the University of Texas System
    Inventors: Damith Gomika UDUGAMASOORIYA, Aaron RAYMOND, John MINNA
  • Patent number: 11660325
    Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: May 30, 2023
    Assignees: University of Houston System, The Board of Regents of the University of Texas System
    Inventors: Damith Gomika Udugamasooriya, Aaron Raymond, John Minna
  • Publication number: 20230151100
    Abstract: The invention relates to a method of selecting a subject for treatment with a combination of an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM), the method comprising: identifying subjects having an AXL-related disease characterised by the presence of cells having modified STK11 activity or expression; and, selecting thus identified subjects for treatment. The invention also relates to an AXL inhibitor (AXLi) and an immune checkpoint modulator (ICM) for use in the treatment of an AXL-related disease.
    Type: Application
    Filed: April 23, 2021
    Publication date: May 18, 2023
    Applicants: BERGENBIO ASA, THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: James LORENS, David MICKLEM, Huiyu LI, Zhida LIU, John MINNA, Rolf BREKKEN
  • Publication number: 20210290724
    Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).
    Type: Application
    Filed: September 19, 2017
    Publication date: September 23, 2021
    Inventors: Damith Gomika Udugamasooriya, Aaron Raymond, John Minna
  • Publication number: 20120108880
    Abstract: Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 3, 2012
    Inventors: Lin Ji, John Minna, Jack Roth, Michael Lerman
  • Patent number: 7781413
    Abstract: The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a cancer cell via gene transfer, or when applied extracellularly. These observations permit new methods for treatment and diagnosis of cancer.
    Type: Grant
    Filed: October 31, 2002
    Date of Patent: August 24, 2010
    Assignee: Board of Regents, The University of Texas System
    Inventors: John Minna, Yoshio Tomizawa, Yoshitaka Sekido, Michael Lerman
  • Publication number: 20070111963
    Abstract: Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.
    Type: Application
    Filed: November 13, 2006
    Publication date: May 17, 2007
    Inventors: David Corey, Bethany Janowski, David Shames, John Minna
  • Publication number: 20030166557
    Abstract: The present invention identifies the semaphorin polypeptide SEMA3B as a tumor suppressor. This molecule can inhibit tumor growth and induce apoptosis of tumor cells when produced internally in a cancer cell via gene transfer, or when applied extracellularly. These observations permit new methods for treatment and diagnosis of cancer.
    Type: Application
    Filed: October 31, 2002
    Publication date: September 4, 2003
    Applicant: Board of Regents, The University of Texas System
    Inventors: John Minna, Yoshio Tomizawa, Yoshitaka Sekido, Michael Lerman
  • Publication number: 20030086911
    Abstract: A novel method of immunization, which can be used either prophylactically or therapeutically, is described. The method comprises coating of antigen presenting cells with a peptide and administering the peptide-coated cells to a mammalian subject to provoke an immune response. Useful peptides include peptides derived from viral or bacterial antigens or mutant oncogene or tumor suppressor gene products. Immunogens, constituted by the peptide-coated cells, are also described.
    Type: Application
    Filed: September 19, 2002
    Publication date: May 8, 2003
    Applicant: Department of Health and Human Services
    Inventors: Jay Berzofsky, Michael Yanuck, David Carbone, John Minna, Hidemi Takahashi
  • Publication number: 20030032050
    Abstract: A novel method of immunization, which can be used either prophylactically or therapeutically, is described. The method comprises coating of antigen presenting cells with a peptide and administering the peptide-coated cells to a mammalian subject to provoke an immune response. Useful peptides include peptides derived from viral or bacterial antigens or mutant oncogene or tumor suppressor gene products. Immunogens, constituted by the peptide-coated cells, are also described.
    Type: Application
    Filed: September 19, 2002
    Publication date: February 13, 2003
    Applicant: The Govt. of the U.S.A., as represented by the Secretary of the Department of H & H Services
    Inventors: Jay A. Berzofsky, Michael Yanuck, David Carbone, John Minna, Hidemi Takahashi